Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects

BACKGROUND: Dabigatran etexilate is a pro-drug of the oral reversible direct thrombin inhibitor dabigatran that interacts with the active site in the catalytic domain of the thrombin molecule. OBJECTIVE: To assess the electrophysiological effects of therapeutic and supratherapeutic doses of dabigatr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ring, Arne, Rathgen, Karin, Stangier, Joachim, Reilly, Paul, Clemens, Andreas, Friedman, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing AG 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634983/
https://www.ncbi.nlm.nih.gov/pubmed/23519576
http://dx.doi.org/10.1007/s40261-013-0058-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634983/
https://www.ncbi.nlm.nih.gov/pubmed/23519576
http://dx.doi.org/10.1007/s40261-013-0058-0

Ejemplares similares